NPS Pharma kept by JMP at market outperform

NPS Pharmaceuticals Inc. was maintained by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $22 per share after second-quarter earnings. JMP believes its osteoporosis drug Preos will reach approvability around second-quarter 2006 and have rapid penetration in the market. NPS shares Wednesday fell $0.50, or 4.46%, to close at $10.70 on volume of 978,402 shares versus the three-month running average of 409,482 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.